Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

By Jaya Ghosh, Lalit Kumar, M. Dimopoulos, A. Spencer, Miles MICHAEL ATTAL, Deepak Dabkara, J. Bajpai. New England Journal of Medicine, 2007

1,440 citations recorded by the source corpus.

Subfields: Hematology, Oncology, Plant Science

View Paper: https://www.semanticscholar.org/paper/32cf6aa2c629905ca550153f79309e6594cf499b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams

In Oncology

1. S. Rajkumar
2. J. Adams

Citations in the corpus

• Continuous lenalidomide treatment for newly diagnosed multiple myeloma. (2012, neutral): “Leukopenia 35 (23) 6 (4) 39 (26) 8 (5) 21 (14) 2 (1)”
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, background): “5 mg/L 5 (8) 3 (9) Albumin level, n (%)”
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013, methodology): “Patients were considered to have high risk disease if FISH studies demonstrated one of the following abnormalities: t(4;14), t(14;16), t(14;20), or loss of p53 gene locus (del 17p or monosomy 17) in the absence of any trisomies.”